Overview of premedication prescription and intake in an oncology day hospital: What do we need to change to improve patient management?

被引:0
作者
Goubil, Annabel [1 ]
Lallier, Laurine [1 ]
Peyrilles, Elodie [2 ]
Coupez, Dahna [3 ]
Gouill, Christele Le [4 ]
Fronteau, Clementine [1 ]
Cormier, Nicolas [1 ]
机构
[1] Nantes Univ, CHU Nantes, Pharm, F-44000 Nantes, France
[2] Canc Inst Paul Papin, Pharm, F-49000 Angers, France
[3] Nantes Univ, CHU Nantes, Oncol, F-44000 Nantes, France
[4] Nantes Univ, CHU Nantes, Oncol Day Hosp, F-44000 Nantes, France
关键词
Premedication; oncology; day hospital; oral forms; compliance with recommendations; CHEMOTHERAPY-INDUCED NAUSEA; ANTIEMETIC GUIDELINES; DOUBLE-BLIND; HYPERSENSITIVITY REACTIONS; IDIOSYNCRATIC REACTIONS; CANCER; PROPHYLAXIS; IMPLEMENTATION; CETIRIZINE; PREVENTION;
D O I
10.1177/10781552231168314
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Premedication of cancer therapy against nausea and vomiting (NV) and hypersensitivity reaction (HS) is essential for good patient management. However, this prescription is not always optimal. Today, as a large part of cancer therapies are administered in day hospitals (DH), premedication taken on the day of the cancer treatment is injected as a 30-min infusion.Objective: To assess compliance with recommendations for premedication prescription and intake; to analyse patient attitude about switching to exclusively oral forms taken at home.Method: The study is conducted in the medical oncology DH of a French Hospital from 17 January to 25 February 2022. The data collection is carried out as an individual interview, associated with the distribution of two questionnaires. Data are coupled with the premedication set up on our software and the last medical report. Intakes are considered optimal when recommendations, tolerance, background, and adherence of the patient are taken into account.Results: Seventy patients were included for interviews. Regarding software prescriptions, our configuration was consistent with recommendations in 100% of cases for HS and 37% for NV. Intakes were compliant in 51.4% of cases, non-compliant in 17.1% and debatable in 31.5%. Disparities between the practices of different physicians were identified. Regarding the feasibility of oral substitution, it could concern 63.5% of patients.Conclusion: This work makes it possible to improve the management of all patients and to make the operation of the care unit more fluid.
引用
收藏
页码:88 / 99
页数:12
相关论文
共 45 条
  • [1] Optimising antiemetic therapy: what are the problems and how can they be overcome?
    Aapro, M
    [J]. CURRENT MEDICAL RESEARCH AND OPINION, 2005, 21 (06) : 885 - 897
  • [2] Adherence to antiemetic guidelines in patients with malignant glioma: a quality improvement project to translate evidence into practice
    Affronti, Mary Lou
    Schneider, Susan M.
    Herndon, James E., II
    Schlundt, Susan
    Friedman, Henry S.
    [J]. SUPPORTIVE CARE IN CANCER, 2014, 22 (07) : 1897 - 1905
  • [3] Palonosetron Versus Other 5-HT3 Receptor Antagonists for Prevention of Chemotherapy-Induced Nausea and Vomiting in Patients With Cancer on Chemotherapy in a Hospital Outpatient Setting
    Balu, Sanjeev
    Buchner, Deborah
    Craver, Chris
    Gayle, Julie
    [J]. CLINICAL THERAPEUTICS, 2011, 33 (04) : 443 - 455
  • [4] A randomized double-blind feasibility study comparing cetirizine and diphenhydramine in the prevention of paclitaxel-associated infusion-related reactions: the PREMED-F1 study
    Beaucage-Charron, Johannie
    Gaudet, Laurence
    Lamothe, Sarah
    Pelletier, Cloe
    Pepin, Anne-Sophie
    Roy, Valerie
    Charpentier, Frederic
    Lordkipanidze, Marie
    Projean, Denis
    Bouchard, Philippe
    Picard, Matthieu
    [J]. SUPPORTIVE CARE IN CANCER, 2022, 30 (04) : 3389 - 3399
  • [5] Hypersensitivity and idiosyncratic reactions to oxaliplatin
    Bhargava, P
    Gammon, D
    McCormick, MJ
    [J]. CANCER, 2004, 100 (01) : 211 - 212
  • [6] Hypersensitivity reactions related to oxaliplatin (OHP)
    Brandi, G
    Pantaleo, MA
    Galli, C
    Falcone, A
    Antonuzzo, A
    Mordenti, P
    Di Marco, MC
    Biasco, G
    [J]. BRITISH JOURNAL OF CANCER, 2003, 89 (03) : 477 - 481
  • [7] Adherence to ESMO clinical recommendations for prophylaxis of chemotherapy-induced nausea and vomiting
    Burmeister, Henning
    Aebi, Stefan
    Studer, Cristina
    Fey, Martin F.
    Gautschi, Oliver
    [J]. SUPPORTIVE CARE IN CANCER, 2012, 20 (01) : 141 - 147
  • [8] The development of a prediction tool to identify cancer patients at high risk for chemotherapy-induced nausea and vomiting
    Dranitsaris, G.
    Molassiotis, A.
    Clemons, M.
    Roeland, E.
    Schwartzberg, L.
    Dielenseger, P.
    Jordan, K.
    Young, A.
    Aapro, M.
    [J]. ANNALS OF ONCOLOGY, 2017, 28 (06) : 1260 - 1267
  • [9] Implementing evidence based antiemetic guidelines in the oncology setting: results of a 4-month prospective intervention study
    Dranitsaris, G
    Leung, P
    Warr, D
    [J]. SUPPORTIVE CARE IN CANCER, 2001, 9 (08) : 611 - 618
  • [10] Premedication Protocols to Prevent Hypersensitivity Reactions to Chemotherapy: a Literature Review
    Faisal, ALMuhizi
    De las Vecillas Sanchez, Leticia
    Gilbert, Lucy
    Copaescu, Ana M.
    Isabwe, Ghislaine A. C.
    [J]. CLINICAL REVIEWS IN ALLERGY & IMMUNOLOGY, 2022, 62 (03) : 534 - 547